Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy

Critical Reviews in Oncogenesis
D Joshua LiaoFazlul H Sarkar

Abstract

C-myc is an oncogene that functions both in the stimulation of cell proliferation and in and apoptosis. C-myc elicits its oncogenic activity by causing immortalization, and to a lesser extent the transformation of cells, in addition to several other mechanisms. C-myc may also enhance or reduce the sensitivity of cancer cells to chemotherapy, but how this dual function is controlled is largely unclear. Cyclin D1 (D1) is another oncogene that drives cell cycle progression; it acts as a growth factor sensor to integrate extracellular signals with the cell cycle machinery, though it may also promote apoptosis. C-Myc collaborates with TGFalpha, epidermal growth factor receptor, Ras, PI3K/Akt, and NF-kappaB. in part via coordination in regulation of D1 expression, because D1 is a common downstream effector of these growth pathways. Coordination of c-Myc with D1 or its upstream activators not only accelerates tumor formation, but also may drive tumor progression to a more aggressive phenotype. Because c-Myc may effect immortalization while D1 or its upstream activators elicit transformation, targeting c-myc and D1 may be a good strategy for cancer prevention. Moreover, since D1 imposes chemoresistance on cancer cells, targeting D1 may...Continue Reading

Citations

Sep 9, 2008·Breast Cancer Research and Treatment·Yuan SunD Joshua Liao
Sep 26, 2009·Pharmaceutical Research·Subapriya RajamanickamRajesh Agarwal
Jan 15, 2011·Journal of Cancer·Yuan SunD Joshua Liao
Apr 23, 2013·Biochimica Et Biophysica Acta·Zakir Khan, Prakash S Bisen
May 16, 2013·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Mark D MurpheyMark J Kransdorf
Aug 24, 2011·Leukemia & Lymphoma·Bettina R BonnBirgit Burkhardt
Jul 18, 2015·Marine Drugs·Li Zhang, Handong Wang
Jun 1, 2010·Expert Opinion on Drug Discovery·John Drewe, Sui Xiong Cai
Jan 23, 2013·Molecular and Cellular Neurosciences·Navjot KaurAnjali Shiras
Mar 22, 2012·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Gaurav DasEdward M Levine
Jan 15, 2014·International Journal of Cancer. Journal International Du Cancer·Wenhao WengYanlei Ma
Jun 10, 2015·The Journal of Experimental Medicine·Soung-Hoon LeeKang-Yell Choi
Dec 6, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Rachel PurcellMichael Sullivan
Jul 20, 2016·Cancers·Kamal AhmedVladimir L Katanaev
Jul 28, 2016·The Journal of Investigative Dermatology·Warangkana LohcharoenkalAndor Pivarcsi
Aug 11, 2016·BMC Complementary and Alternative Medicine·Lavanya ReddivariJairam K P Vanamala
Jan 20, 2017·International Journal of Oncology·Chi-Cheng LuGow-Chin Yen
Jun 28, 2018·Molecular Neurobiology·Diana MatiasVivaldo Moura-Neto
Oct 4, 2020·International Journal of Molecular Sciences·Ji Eun JungJi Hye Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis